Provention Bio logo
Provention Bio PRVB
report update icon

Quarterly report 2022-Q3
added 05-16-2026

Provention Bio Financial Statements 2022-2011 | PRVB

Annual Financial Statements Provention Bio

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.79 B 355 M 889 M 607 M 39.7 M - - - - - - -

Shares

74.7 M 63.1 M 52.5 M 40.7 M 22.4 M 9.37 M 7.64 M - - - - -

Historical Prices

23.9 5.62 16.9 14.9 1.77 - - - - - - -

Net Income

-114 M -114 M -98.6 M -43.3 M -26.5 M -9.13 M -165 K - - - - -

Revenue

12.9 M 1.4 M - - - - - - - - - -

Operating Income

-128 M -116 M -99.7 M -44.4 M -26.8 M -9.14 M -165 K - - - - -

Interest Expense

1.04 M - - - - - - - - - - -

EBITDA

-128 M -115 M -99.7 M -44.4 M -26.8 M -9.14 M -165 K - - - - -

Operating Expenses

141 M 117 M 99.7 M 44.4 M 26.8 M 9.14 M 165 K - - - - -

General and Administrative Expenses

64.1 M 47.3 M 33.3 M 8.01 M 4.16 M 1.46 M 165 K - - - - -

All numbers in USD currency

Quarterly Income Statement Provention Bio

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 83.1 M 64.7 M 63.4 M 63.4 M 63.4 M 63.4 M 62.3 M 56.5 M 56.3 K 49.2 K 47.7 K 47.7 M 40.5 M 37.4 M 37.4 M 37.4 M 32 M 10 M 10 M 10 M 10 M 9.47 M - 7.64 M - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- -28.6 M -29.7 M -22 M - -27 M -29.1 M -32.4 M - -31.3 M -22.1 M -12.6 M - -9.77 M -12 M -11 M - -5.39 M -10.3 M -5.06 M - -1.36 M -4.04 M - -165 K - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- 756 K 746 K 580 K - 678 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- -29.1 M -29.8 M -29.1 M - -27.1 M -30.2 M -32.5 M - -31.4 M -22.8 M -12.9 M - -9.97 M -12.3 M -11.3 M - -5.41 M -10.2 M -5.04 M - -1.38 M -3.99 M - -165 K - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 255 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- -29 M -29.6 M -28.9 M - -27 M -30.1 M -32.4 M - -31.4 M -22.8 M -12.9 M - -9.97 M -12.3 M -11.3 M - -5.41 M -10.2 M -5.04 M - -1.38 M -3.99 M - -165 K - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- 29.8 M 30.6 M 29.7 M - 27.8 M 30.2 M 32.5 M - 31.4 M 22.8 M 12.9 M - 9.97 M 12.3 M 11.3 M - 5.41 M 10.2 M 5.04 M - 1.38 M 3.99 M - 165 K - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- 13.5 M 14 M 12.3 M - 10 M 13.2 M 12.8 M - 9.75 M 7.76 M 3.78 M - 2.65 M 1.71 M 1.24 M - 1.27 M 1 M 653 K - 488 K 256 K - 165 K - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Provention Bio PRVB
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Provention Bio plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Revolution Medicines Revolution Medicines
RVMD
$ 207.32 0.24 % $ 39.4 B usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 101.8 0.08 % $ 6.62 B usaUSA
Rezolute Rezolute
RZLT
$ 4.4 0.88 % $ 334 M usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 3.45 0.77 % $ 874 M usaUSA
Seer Seer
SEER
$ 1.95 0.26 % $ 108 M usaUSA
Precigen Precigen
PGEN
$ 6.87 0.14 % $ 2.15 B usaUSA
SIGA Technologies SIGA Technologies
SIGA
$ 3.2 1.86 % $ 229 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 19.94 0.05 % $ 1.73 B usaUSA
Soligenix Soligenix
SNGX
$ 0.38 1.18 % $ 1.97 M usaUSA
Spruce Biosciences Spruce Biosciences
SPRB
$ 59.09 2.0 % $ 45.3 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 20.94 0.04 % $ 2.1 B usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
$ 30.05 0.81 % $ 1.78 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 19.1 0.34 % $ 162 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 6.5 0.29 % $ 452 M usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 42.43 0.23 % $ 2.4 B usaUSA
Savara Savara
SVRA
$ 5.53 2.98 % $ 1.23 B usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.24 0.45 % $ 1.52 M chinaChina
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 18.32 1.49 % $ 28.9 B japanJapan
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.31 0.01 % $ 11.3 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.98 2.06 % $ 77.7 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 36.76 1.21 % $ 42.1 B israelIsrael
TG Therapeutics TG Therapeutics
TGTX
$ 55.74 0.58 % $ 8.04 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 16.82 1.17 % $ 2.27 B usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 5.48 0.54 % $ 1.75 B usaUSA
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 69.37 0.35 % $ 193 M israelIsrael
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 43.82 0.02 % $ 2.11 B israelIsrael
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 497.97 2.12 % $ 22.1 B usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.19 0.41 % $ 66.7 M usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 57.42 3.78 % $ 6.59 B usaUSA
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
NextCure NextCure
NXTC
$ 8.42 7.67 % $ 23.9 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 5.26 0.75 % $ 56 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 23.17 1.09 % $ 2.36 B usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
- 7.23 % $ 2.72 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 528.9 0.22 % $ 135 B usaUSA
Verastem Verastem
VSTM
$ 8.08 0.55 % $ 560 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
$ 32.79 0.03 % $ 130 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 3.4 3.85 % $ 200 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 4.91 1.03 % $ 828 M singaporeSingapore
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 13.16 0.15 % $ 112 M usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 4.28 0.86 % $ 7.28 M usaUSA
XBiotech XBiotech
XBIT
$ 2.18 0.23 % $ 66.5 M usaUSA
Exicure Exicure
XCUR
$ 1.41 12.8 % $ 8.88 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 59.55 0.18 % $ 4.72 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 8.48 0.12 % $ 1.36 B usaUSA